```
FILE 'HOME' ENTERED AT 18:02:36 ON 28 MAR 2009

=> file biosis medline caplus wpids uspatfull
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                   1.76       1.76

FILE 'BIOSIS' ENTERED AT 18:07:29 ON 28 MAR 2009
Copyright (c) 2009 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 18:07:29 ON 28 MAR 2009

FILE 'CAPLUS' ENTERED AT 18:07:29 ON 28 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 18:07:29 ON 28 MAR 2009
COPYRIGHT (C) 2009 THOMSON REUTERS

FILE 'USPATFULL' ENTERED AT 18:07:29 ON 28 MAR 2009
CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

*** YOU HAVE NEW MAIL ***

=> s hairpin polynucleotide and solid support
L1          23 HAIRPIN POLYNUCLEOTIDE AND SOLID SUPPORT

=> s l1 and sulfur
L2          16 L1 AND SULFUR

=> dup rem l2
PROCESSING COMPLETED FOR L2
L3           15 DUP REM L2 (1 DUPLICATE REMOVED)

=> s l3 and linker
L4          14 L3 AND LINKER

=> d l4 bib abs 1-14

L4   ANSWER 1 OF 14  CAPLUS  COPYRIGHT 2009 ACS on STN
AN   2005:451395  CAPLUS
DN   142:477754
TI   Hairpin polynucleotide having a sulfur-based
     nucleophile attached to an internal nucleotide in the hairpin through a
     linker to enable binding to a solid support
     for use in arrays
IN   Ellis, Darren James; Barnes, Colin Lloyd; Swerdlow, Harold Philip; Brown,
     Tom
PA   Solexa Limited, UK
SO   PCT Int. Appl., 43 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
PI   WO 2005047301        A1    20050526    WO 2004-GB4707         20041108
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
```

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG

EP 1692152 A1 20060823 EP 2004-798430 20041108
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS

US 20070269806 A1 20071122 US 2007-578460 20070222

PRAI GB 2003-26073 A 20031107

WO 2004-GB4707 W 20041108

AB The invention provides a hairpin polynucleotide, having a loop and a stem region, characterized in that a sulfur -based nucleophile is attached to an internal nucleotide in the hairpin through a linker to enable binding to a solid support. In another aspect, the invention provides a method of making a hairpin polynucleotide, having a loop and a stem region, having a sulfur-based nucleophile attached to an internal nucleotide in the hairpin through a linker to enable binding to a solid support, which method comprises incorporating the sulfur-based nucleophile into said internal nucleotide before, after or during formation of the hairpin polynucleotide, particularly before or during formation. In a further aspect, the invention provides an array of hairpin polynucleotides as described herein immobilized on a surface of a solid support by reaction between the sulfur-based nucleophile and the surface of the solid support. The present invention is based on the surprising finding that when hairpin polynucleotides are attached to a solid support, e.g. for use in the preparation of single mol. arrays (SMAs), by reaction of a sulfur-based nucleophile with the solid support , improved adhesion to the solid support is effected as compared to attachment through backbone phosphorothioate moieties. The sulfur-based nucleophile may be directly attached to the hairpin although it is preferably indirectly attached through a linker. Attachment is by way of an internal nucleotide within the hairpin, that is to say that the sulfur-based nucleophile is not connected directly or through a linker to a nucleotide at either terminus of the hairpin.

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 14 USPATFULL on STN
AN 2008:97974 USPATFULL
TI Compositions and methods for detecting and treating renal injury and inflammation
IN Dworkin, Lance, Providence, RI, UNITED STATES
Gong, Rujun, Providence, RI, UNITED STATES
PA Rhode Island Hospital (U.S. corporation)
PI US 20080085324 A1 20080410
AI US 2007-731250 A1 20070329 (11)
PRAI US 2006-828378P 20061005 (60)
DT Utility
FS APPLICATION
LREP ROPES & GRAY LLP, PATENT DOCKETING 39/41, ONE INTERNATIONAL PLACE, BOSTON, MA, 02110-2624, US
CLMN Number of Claims: 64

ECL Exemplary Claim: 1
DRWN 19 Drawing Page(s)
LN.CNT 3567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Renal injury and inflammation is diagnosed by detecting an elevation in GSK3b level or activity. Inflammation of bodily tissues such as renal tissue is inhibited by administration of GSK3b inhibitory compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 14 USPATFULL on STN
AN 2007:308708 USPATFULL
TI Polynucleotide Arrays
IN Ellis, Darren James, Essex, UNITED KINGDOM
Barnes, Colin Llyod, Essex, UNITED KINGDOM
Swerdlow, Harold Philip, Essex, UNITED KINGDOM
Brown, Tom, Highfield, UNITED KINGDOM
PI US 20070269806 A1 20071122
AI US 2004-578460 A1 20041108 (10)
WO 2004-GB4707 20041108
20070222 PCT 371 date
PRAI GB 2003-26073 20031107
DT Utility
FS APPLICATION
LREP KLAUBER & JACKSON, 411 HACKENSACK AVENUE, HACKENSACK, NJ, 07601, US
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 909
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides a hairpin polynucleotide, having a loop and a stem region, characterised in that a sulfur -based nucleophile is attached to an internal nucleotide in the hairpin through a linker to enable binding to a solid support.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 14 USPATFULL on STN
AN 2007:154022 USPATFULL
TI Immunomodulatory compositions and uses therefor
IN Smith, Craig A., Seattle, WA, UNITED STATES
Wiley, Steven, Seattle, WA, UNITED STATES
Kaykas, Ajamete, Seattle, WA, UNITED STATES
Vakili, Jalal, Seattle, WA, UNITED STATES
Probst, Peter, Seattle, WA, UNITED STATES
PA Viral Logic Systems Technology Corp., Seattle, WA, UNITED STATES (U.S. corporation)
PI US 20070134234 A1 20070614
AI US 2006-541449 A1 20060929 (11)
PRAI US 2005-721876P 20050929 (60)
US 2006-784710P 20060322 (60)
US 2006-801992P 20060519 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 5400, SEATTLE, WA, 98104, US
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN 19 Drawing Page(s)
LN.CNT 6422

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The poxvirus proteins designated A41L and 130L bind to three receptor-like protein tyrosine phosphatases (RPTP), leukocyte common antigen related protein (LAR), RPTP-δ, and RPTP-σ, that are present on the cell surface of immune cells. When a host is infected with the poxvirus, binding of A41L to cell surface proteins on the host cells results in suppression of the immune response. The present invention provides agents such as antibodies, and antigen-binding fragments thereof, small molecules, aptamers, small interfering RNAs, and peptide-IgFc fusion polypeptides that interact with one or more of LAR, RPTP-δ, and RPTP-σ expressed by immune cells or interact with a polynucleotide encoding the RPTP. Also provided are RPTP Ig domain oligomers and Fc fusion polypeptides. Such agents are useful for treating an immunological disorder in a subject according to the methods described herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 14 USPATFULL on STN
AN 2006:262261 USPATFULL
TI Highly functional short hairpin RNA
IN Vermeulen, Annaleen, Lafayette, CO, UNITED STATES
Reynolds, Angela, Conifer, CO, UNITED STATES
Karpilow, Jon, Boulder, CO, UNITED STATES
Leake, Devin, Denver, CO, UNITED STATES
Cheng, Xiaoqin, Broomfield, CO, UNITED STATES
Hartsel, Stephanie A., Berthoud, CO, UNITED STATES
Khvorova, Anastasia, Boulder, CO, UNITED STATES
PA Dharmacon, Inc. (U.S. corporation)
PI US 20060223777 A1 20061005
AI US 2006-390829 A1 20060328 (11)
PRAI US 2005-666474P 20050329 (60)
DT Utility
FS APPLICATION
LREP WORKMAN NYDEGGER, (F/K/A WORKMAN NYDEGGER & SEELEY), 60 EAST SOUTH TEMPLE, 1000 EAGLE GATE TOWER, SALT LAKE CITY, UT, 84111, US
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN 28 Drawing Page(s)
LN.CNT 3125
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides improved hairpin and fractured hairpin constructs for use in gene silencing through the RNA interference pathway. An exemplary short hairpin polynucleotide for use in gene silencing can include a polynucleotide having from about 42 nucleotides to about 106 nucleotides configured for being processed by Dicer. The polynucleotide can include a first region having from about 19 to about 35 nucleotides, a loop region coupled to the first region, the loop region having from about 4 to about 30 nucleotides, and a second region having from about 19 to about 35 nucleotides and having at least about 80% complementarity to the first region. Optionally, one of the first region or second region can have an overhang having less than about 6 nucleotides. Also, the short hairpin can be formed of a plurality of polynucleotides that cooperate to form a hairpin structure.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 6 OF 14 USPATFULL on STN
AN 2003:293875 USPATFULL
TI RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)

IN Morrissey, David, Boulder, CO, UNITED STATES
McSwiggen, James A., Boulder, CO, UNITED STATES
Beigelman, Leonid, Longmont, CO, UNITED STATES
PI US 20030206887 A1 20031106
AI US 2002-244647 A1 20020916 (10)
RLI Continuation-in-part of Ser. No. WO 2002-US9187, filed on 26 Mar 2002, PENDING Continuation-in-part of Ser. No. US 2001-877478, filed on 8 Jun 2001, ABANDONED Continuation-in-part of Ser. No. US 2000-696347, filed on 24 Oct 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-636385, filed on 9 Aug 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-531025, filed on 20 Mar 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-436430, filed on 8 Nov 1999, PENDING Continuation of Ser. No. US 1994-193627, filed on 7 Feb 1994, GRANTED, Pat. No. US 6017756 Continuation of Ser. No. US 1992-882712, filed on 14 May 1992, ABANDONED
PRAI US 2001-296876P 20010608 (60)
US 2001-335059P 20011024 (60)
US 2001-337055P 20011205 (60)
US 2002-358580P 20020220 (60)
US 2002-363124P 20020311 (60)
US 2002-386782P 20020606 (60)
US 2002-406784P 20020829 (60)
US 2002-408378P 20020905 (60)
US 2002-409293P 20020909 (60)
DT Utility
FS APPLICATION
LREP MCDONNELL BOEHNEN HULBERT & BERGHOFF, 300 SOUTH WACKER DRIVE, SUITE 3200, CHICAGO, IL, 60606
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 13 Drawing Page(s)
LN.CNT 6174
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention concerns methods and reagents useful in modulating hepatitis B virus (HBV) gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to short interfering nucleic acid (siNA) or short interfering RNA (siRNA) molecules capable of mediating RNA interference (RNAi) against against hepatitis B virus (HBV).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 7 OF 14 USPATFULL on STN
AN 2003:251164 USPATFULL
TI RNA interference mediated inhibition of HIV gene expression using short interfering RNA
IN McSwiggen, James A., Boulder, CO, UNITED STATES
PI US 20030175950 A1 20030918
AI US 2002-225023 A1 20020821 (10)
RLI Continuation-in-part of Ser. No. US 2002-157580, filed on 29 May 2002, PENDING
PRAI US 2002-398036P 20020723 (60)
US 2001-294140P 20010529 (60)
DT Utility
FS APPLICATION
LREP MCDONNELL BOEHNEN HULBERT & BERGHOFF, 300 SOUTH WACKER DRIVE, SUITE 3200, CHICAGO, IL, 60606
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)

LN.CNT 5114
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention concerns methods and reagents useful in modulating HIV gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small interfering RNA (siRNA) molecules capable of mediating RNA interference (RNAi) against HIV polypeptide and polynucleotide targets.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 8 OF 14 USPATFULL on STN
AN 2003:244482 USPATFULL
TI RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
IN McSwiggen, James A., Boulder, CO, UNITED STATES
PI US 20030170891 A1 20030911
AI US 2002-251117 A1 20020919 (10)
RLI Continuation-in-part of Ser. No. US 2001-916466, filed on 25 Jul 2001, PENDING Continuation-in-part of Ser. No. US 2002-163552, filed on 6 Jun 2002, PENDING
PRAI US 2002-358580P 20020220 (60)
US 2002-393924P 20020703 (60)
US 2001-296249P 20010606 (60)
DT Utility
FS APPLICATION
LREP MCDONNELL BOEHNEN HULBERT & BERGHOFF, 300 SOUTH WACKER DRIVE, SUITE 3200, CHICAGO, IL, 60606
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN 22 Drawing Page(s)
LN.CNT 11316
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention concerns methods and reagents useful in modulating EGFR (HER1, HER2, HER3, and/or HER4) gene expression in a variety of applications, including use in therapeutic, diagnostic, agricultural, target validation, and genomic discovery applications. Specifically, the invention relates to short interfering nucleic acid (siNA) or short interfering RNA (siRNA) molecules capable of mediating RNA interference (RNAi) against epidermal growth factor receptor targets.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 9 OF 14 USPATFULL on STN
AN 2003:237907 USPATFULL
TI Compositions and methods for the therapy and diagnosis of colon cancer
IN King, Gordon E., Shoreline, WA, UNITED STATES
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES
Xu, Jiangchun, Bellevue, WA, UNITED STATES
Secrist, Heather, Seattle, WA, UNITED STATES
Jiang, Yuqiu, Kent, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 20030166064 A1 20030904
AI US 2002-99926 A1 20020314 (10)
RLI Continuation-in-part of Ser. No. US 2001-33528, filed on 26 Dec 2001, PENDING Continuation-in-part of Ser. No. US 2001-920300, filed on 31 Jul 2001, PENDING
PRAI US 2001-302051P 20010629 (60)
US 2001-279763P 20010328 (60)
US 2000-223283P 20000803 (60)
DT Utility

FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8531
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 10 OF 14 USPATFULL on STN
AN 2003:213869 USPATFULL
TI RNA interference mediated inhibition of prostaglandin D2 receptor (PTGDR) and prostaglandin D2 synthetase (PTGDS) gene expression using short interfering RNA
IN Fosnaugh, Kathy, Longmont, CO, UNITED STATES
McSwiggen, James A., Boulder, CO, UNITED STATES
PA Ribozyme Pharmaceuticals, Inc. (U.S. corporation)
PI US 20030148507 A1 20030807
AI US 2002-226992 A1 20020823 (10)
PRAI US 2001-315315P 20010828 (60)
DT Utility
FS APPLICATION
LREP MCDONNELL BOEHNEN HULBERT & BERGHOFF, 300 SOUTH WACKER DRIVE, SUITE 3200, CHICAGO, IL, 60606
CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 3848
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention concerns methods and reagents useful in modulating prostaglandin D2 receptor (PTGDR) and/or prostaglandin D2 synthetase (PTGDS) gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small interfering RNA (siRNA) molecules capable of mediating RNA interference (RNAi) against PTGDR and/or PTGDS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 11 OF 14 USPATFULL on STN
AN 2003:207374 USPATFULL
TI RNA interference mediated inhibition of adenosine A1 receptor (ADORA1) gene expression using short interfering RNA
IN Fosnaugh, Kathy, Longmont, CO, UNITED STATES
McSwiggen, James A., Boulder, CO, UNITED STATES
PI US 20030143732 A1 20030731
AI US 2002-224005 A1 20020820 (10)
PRAI US 2001-315315P 20010828 (60)
DT Utility
FS APPLICATION
LREP MCDONNELL BOEHNEN HULBERT & BERGHOFF, 300 SOUTH WACKER DRIVE, SUITE

3200, CHICAGO, IL, 60606
CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 3965
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention concerns methods and reagents useful in modulating adenosine A1 receptor (ADORA1) gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small interfering RNA (siRNA) molecules capable of mediating RNA interference (RNAi) against ADORA1 and related receptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 12 OF 14 USPATFULL on STN
AN 2003:106233 USPATFULL
TI Compositions and methods for the therapy and diagnosis of pancreatic cancer
IN Benson, Darin R., Seattle, WA, UNITED STATES
Kalos, Michael D., Seattle, WA, UNITED STATES
Lodes, Michael J., Seattle, WA, UNITED STATES
Persing, David H., Redmond, WA, UNITED STATES
Hepler, William T., Seattle, WA, UNITED STATES
Jiang, Yuqiu, Kent, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 20030073144 A1 20030417
AI US 2002-60036 A1 20020130 (10)
PRAI US 2001-333626P 20011127 (60)
US 2001-305484P 20010712 (60)
US 2001-265305P 20010130 (60)
US 2001-267568P 20010209 (60)
US 2001-313999P 20010820 (60)
US 2001-291631P 20010516 (60)
US 2001-287112P 20010428 (60)
US 2001-278651P 20010321 (60)
US 2001-265682P 20010131 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 14253
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the therapy and diagnosis of cancer, particularly pancreatic cancer, are disclosed. Illustrative compositions comprise one or more pancreatic tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly pancreatic cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 13 OF 14 USPATFULL on STN
AN 2002:272801 USPATFULL
TI Compositions and methods for the therapy and diagnosis of colon cancer
IN Stolk, John A., Bothell, WA, UNITED STATES

Xu, Jiangchun, Bellevue, WA, UNITED STATES
Chenault, Ruth A., Seattle, WA, UNITED STATES
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 20020150922 A1 20021017
AI US 2001-998598 A1 20011116 (9)
PRAI US 2001-304037P 20010710 (60)
US 2001-279670P 20010328 (60)
US 2001-267011P 20010206 (60)
US 2000-252222P 20001120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 9233
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 14 OF 14 USPATFULL on STN
AN 2002:243051 USPATFULL
TI Compositions and methods for the therapy and diagnosis of ovarian cancer
IN Algate, Paul A., Issaquah, WA, UNITED STATES
Jones, Robert, Seattle, WA, UNITED STATES
Harlocker, Susan L., Seattle, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 20020132237 A1 20020919
AI US 2001-867701 A1 20010529 (9)
PRAI US 2000-207484P 20000526 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 25718
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>